Click here for slides on this topic


Angiotensin-converting enzyme (ACE)

A protein that converts angiotensin I to angiotensin II. Angiotensin II is the active form of angiotensin and plays an important role in vasoconstriction. The action of angiotensin II results in an increase in blood pressure and a decrease in glomerular filtration rate.


The following content matched the glossary term: Angiotensin-converting enzyme (ACE)

American Heart Association (AHA) Scientific Sessions 2012

Top

Exclusive coverage of late-breaking data from the American Heart Association Scientific Sessions, November 3-7, 2012 in Los Angeles, California are featured in this issue of OnsiteInsight®.

Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease

Top

Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Arch Intern Med. 2008;148(1):30-48.

A managed care organization's use of integrated health management to improve secondary prevention of coronary artery disease

Top

Berthiaume JT, Davis J, Taira DA, Thein KK. A managed care organization's use of integrated health management to improve secondary prevention of coronary artery disease. Am J Manag Care. 2007;13(3):142-7. OBJECTIVE: To evaluate the effect of a managed care organization's multifactorial intervention program in optimizing secondary prevention of coronary artery disease (CAD).

Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes

Top

Winkelmayer WC, Fischer MA, Schneeweiss S, Wang PS, Levin R, Avorn J. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am J Kidney Dis. 2005;46:1080-1087. National guidelines recommend angiotensin-converting enzyme (ACE)-inhibitor or angiotensin receptor blocker (ARB) therapy in patients with diabetes who also have hypertension and/or proteinuria to retard the progression of renal damage. However, little is known about the adequacy of adherence to these guidelines in elderly patients with diabetes and predictors of such appropriate ACE-inhibitor or ARB use.

For those intolerant to ACE inhibitors and ARBs, what is the best therapy for reducing the risk of diabetic nephropathy?

Top

Penmetsa S, Simmons M, Daugird A. For those intolerant to ACE inhibitors and ARBs, what is the best therapy for reducing the risk of diabetic nephropathy? J Fam Pract. 2005;54:711-713. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) are the first-line agents for reducing the risk of diabetic nephropathy.

Development of diabetes is retarded by ACE inhibition in hypertensive patients--a subanalysis of the Captopril Prevention Project (CAPPP)

Top

Niklason A, Hedner T, Niskanen L, Lanke J. Development of diabetes is retarded by ACE inhibition in hypertensive patients--a subanalysis of the Captopril Prevention Project (CAPPP). J Hypertens. 2004;22:645-652. The Captopril Prevention Project (CAPPP) was designed as a prospective intervention trial comparing the effect of a treatment based on the angiotensin-converting enzyme (ACE) inhibitor captopril with that of a conventional diuretic and/or beta-blocker-based therapy, in 10,985 hypertensive patients.



Slide Library Results

Search Results for: Angiotensin-converting enzyme (ACE) Slides Found: 5
New Onset Diabetes in Clinical Trials of Antihypertensive Drugs: A Meta-analysis
Recommended Treatment of Hypertension in Diabetes
ESH/ESC Hypertension Guidelines: Compelling Indications for Hypertension Treatment
ESH/ESC Hypertension Guidelines: Hypertension Treatment Options
ESH/ESC Hypertension Guidelines: Hypertension Treatment for Patients With Heart Disease